AC 7700
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571429

CAS#: 253426-24-3

Description: AC 7700, also known as Ombrabulin HCl, is a vascular disrupting agent. It has been used to slow the growth of tumors by disrupting blood flow and thus stopping nutrient delivery to the tumor. The drug inhibits tumor growth in a number of organs.


Chemical Structure

img
AC 7700
CAS# 253426-24-3

Theoretical Analysis

MedKoo Cat#: 571429
Name: AC 7700
CAS#: 253426-24-3
Chemical Formula: C21H27ClN2O6
Exact Mass:
Molecular Weight: 438.91
Elemental Analysis: C, 57.47; H, 6.20; Cl, 8.08; N, 6.38; O, 21.87

Price and Availability

Size Price Availability Quantity
5.0mg USD 230.0 2 Weeks
25.0mg USD 380.0 2 Weeks
Bulk inquiry

Synonym: AC 7700; AC7700; AC-7700; Ombrabulin HCl

IUPAC/Chemical Name: Propanamide, 2-amino-3-hydroxy-N-(2-methoxy-5-((1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl)phenyl)-, monohydrochloride, (2S)-

InChi Key: UQNRTPFLTRZEIM-MRWUDIQNSA-N

InChi Code: InChI=1S/C21H26N2O6.ClH/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3;/h5-11,15,24H,12,22H2,1-4H3,(H,23,25);1H/b6-5-;/t15-;/m0./s1

SMILES Code: O=C(NC1=CC(/C=C\C2=CC(OC)=C(OC)C(OC)=C2)=CC=C1OC)[C@@H](N)CO.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 438.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4
derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer. 2003
Oct 6;89(7):1334-44. PubMed PMID: 14520469; PubMed Central PMCID: PMC2394288.

2: Hori K, Saito S, Sato Y, Akita H, Kawaguchi T, Sugiyama K, Sato H.
Differential relationship between changes in tumour size and microcirculatory
functions induced by therapy with an antivascular drug and with cytotoxic drugs.
implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur
J Cancer. 2003 Sep;39(13):1957-66. PubMed PMID: 12932676.

3: Hori K, Saito S, Nihei Y, Suzuki M, Sato Y. Antitumor effects due to
irreversible stoppage of tumor tissue blood flow: evaluation of a novel
combretastatin A-4 derivative, AC7700. Jpn J Cancer Res. 1999 Sep;90(9):1026-38.
PubMed PMID: 10551334.

4: Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700,
strongly stanches tumour blood flow and inhibits growth of tumours developing in
various tissues and organs. Br J Cancer. 2002 May 20;86(10):1604-14. PubMed PMID:
12085211; PubMed Central PMCID: PMC2746587.

5: Hori K, Saito S, Sato Y, Kubota K. Stoppage of blood flow in
3-methylcholanthrene-induced autochthonous primary tumor due to a novel
combretastatin A-4 derivative, AC7700, and its antitumor effect. Med Sci Monit.
2001 Jan-Feb;7(1):26-33. PubMed PMID: 11208488.

6: Hori K. Antineoplastic strategy: irreversible tumor blood flow stasis induced
by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy. 2005
Oct;51(6):357-60. Epub 2005 Oct 14. Review. PubMed PMID: 16227690.

7: Hori K, Furumoto S, Kubota K. Tumor blood flow interruption after radiotherapy
strongly inhibits tumor regrowth. Cancer Sci. 2008 Jul;99(7):1485-91. doi:
10.1111/j.1349-7006.2008.00834.x. Epub 2008 Apr 29. PubMed PMID: 18452559.

8: Hori K, Akita H, Nonaka H, Sumiyoshi A, Taki Y. Prevention of cancer
recurrence in tumor margins by stopping microcirculation in the tumor and
tumor-host interface. Cancer Sci. 2014 Sep;105(9):1196-204. doi:
10.1111/cas.12477. Epub 2014 Sep 18. PubMed PMID: 24981848; PubMed Central PMCID:
PMC4462395.

9: Nihei Y, Suga Y, Morinaga Y, Ohishi K, Okano A, Ohsumi K, Hatanaka T, Nakagawa
R, Tsuji T, Akiyama Y, Saito S, Hori K, Sato Y, Tsuruo T. A novel combretastatin
A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid
tumors and orthotopically transplanted tumors. Jpn J Cancer Res. 1999
Sep;90(9):1016-25. PubMed PMID: 10551333.

10: Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M. Combination effect
of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine
and human tumors in vivo. Cancer Sci. 2003 Feb;94(2):200-4. PubMed PMID:
12708497.

11: Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K,
Sato Y. Evaluation of antivascular and antimitotic effects of tubulin binding
agents in solid tumor therapy. Jpn J Cancer Res. 1999 Dec;90(12):1387-95. PubMed
PMID: 10665658.

12: von Angerer E. Tubulin as a target for anticancer drugs. Curr Opin Drug
Discov Devel. 2000 Sep;3(5):575-84. PubMed PMID: 19649885.

13: Ohsumi K, Hatanaka T, Nakagawa R, Fukuda Y, Morinaga Y, Suga Y, Nihei Y,
Ohishi K, Akiyama Y, Tsuji T. Synthesis and antitumor activities of amino acid
prodrugs of amino-combretastatins. Anticancer Drug Des. 1999 Dec;14(6):539-48.
PubMed PMID: 10834274.

14: Ohno T, Kawano K, Sasaki A, Aramaki M, Tahara K, Etoh T, Kitano S. Antitumor
and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat
liver cancer. Int J Clin Oncol. 2002 Jun;7(3):171-6. PubMed PMID: 12109519.

15: Hori K, Saito S. Induction of tumour blood flow stasis and necrosis: a new
function for epinephrine similar to that of combretastatin A-4 derivative AVE8062
(AC7700). Br J Cancer. 2004 Jan 26;90(2):549-53. PubMed PMID: 14735207; PubMed
Central PMCID: PMC2409553.

AC 7700

5.0mg / USD 230.0